Angina, Unstable

• 

  Subject Areas on Research

  • "Hot" unstable angina--is it worse than subacute unstable angina? Results from the GUARANTEE Registry. 
  • 2002 update to the ACC/AHA guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction: implications for emergency department practice. 
  • 2012 ACCF/AHA focused update incorporated into the ACCF/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 
  • 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 
  • 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 
  • A comparison of the clinical impact of bleeding measured by two different classifications among patients with acute coronary syndromes. 
  • A framework for quality improvement: an analysis of factors responsible for improvement at hospitals participating in the Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes with Early Implementation of the ACC/AHA Guidelines (CRUSADE) quality improvement initiative. 
  • A multicenter, randomized trial of percutaneous coronary intervention versus bypass surgery in high-risk unstable angina patients. The AWESOME (Veterans Affairs Cooperative Study #385, angina with extremely serious operative mortality evaluation) investigators from the Cooperative Studies Program of the Department of Veterans Affairs. 
  • A symposium: safety issues concerning the use of glycoprotein IIb-IIIa inhibitors in the management of acute coronary syndromes. 
  • A tale of two trials: a comparison of the post-acute coronary syndrome lipid-lowering trials A to Z and PROVE IT-TIMI 22. 
  • A validated prediction model for all forms of acute coronary syndrome: estimating the risk of 6-month postdischarge death in an international registry. 
  • ACC/AHA 2002 guideline update for exercise testing: summary article. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1997 Exercise Testing Guidelines). 
  • ACC/AHA 2002 guideline update for exercise testing: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1997 Exercise Testing Guidelines). 
  • Activation of the inflammation, coagulation, and fibrinolysis systems, without influence of abciximab infusion in patients with non-ST-elevation acute coronary syndromes treated with dalteparin: a GUSTO IV substudy. 
  • Acute Catheterization and Urgent Intervention Triage strategY (ACUITY) trial: study design and rationale. 
  • Acute clopidogrel use and outcomes in patients with non-ST-segment elevation acute coronary syndromes undergoing coronary artery bypass surgery. 
  • Acute coronary care in the elderly, part I: Non-ST-segment-elevation acute coronary syndromes: a scientific statement for healthcare professionals from the American Heart Association Council on Clinical Cardiology: in collaboration with the Society of Geriatric Cardiology. 
  • Acute coronary care in the elderly, part II: ST-segment-elevation myocardial infarction: a scientific statement for healthcare professionals from the American Heart Association Council on Clinical Cardiology: in collaboration with the Society of Geriatric Cardiology. 
  • Acute coronary syndromes and diabetes mellitus. 
  • Acute coronary syndromes in deployed military personnel. 
  • Acute coronary syndromes in patients with diabetes mellitus: diagnosis, prognosis, and current management strategies. 
  • Acute coronary syndromes in the GUSTO-IIb trial: prognostic insights and impact of recurrent ischemia. The GUSTO-IIb Investigators. 
  • Acute coronary syndromes: introducing new therapies into established guidelines. 
  • Acute reduction of lipoprotein(a) by tissue-type plasminogen activator. 
  • Acute results, complications, and effect of lesion characteristics on outcome with the solid-state, pulsed-wave, mid-infrared laser angioplasty system: final multicenter registry report. Holmium:YAG Laser Multicenter Investigators. 
  • Age and persistent use of cardiovascular medication after acute coronary syndrome: results from medication applied and sustained over time. 
  • Aggressive clinical pattern of angina at restenosis following coronary angioplasty in unstable angina. 
  • Alcohol septal ablation for the treatment of hypertrophic obstructive cardiomyopathy. A multicenter North American registry. 
  • Alirocumab Reduces Total Hospitalizations and Increases Days Alive and Out of Hospital in the ODYSSEY OUTCOMES Trial. 
  • An overview of the results of the EPIC trial. 
  • Angiographic morphology in unstable angina pectoris. 
  • Anticoagulant therapy in unstable angina. 
  • Antithrombotic therapy in medically managed patients with non-ST-segment elevation acute coronary syndromes. 
  • Aortic counterpulsation: a review of the hemodynamic effects and indications for use. 
  • Apixaban with antiplatelet therapy after acute coronary syndrome. 
  • Applying novel methods to assess clinical outcomes: insights from the TRILOGY ACS trial. 
  • Applying the resource-based relative value scale to the Emory angioplasty versus surgery trial. 
  • Appropriateness of percutaneous coronary intervention. 
  • Arterial stiffness and cardiovascular events: the Framingham Heart Study. 
  • Assessing performance reports to individual providers in the care of acute coronary syndromes. 
  • Assessing the clinical and economic burden of coronary artery disease: 1986-1998. 
  • Association Between Very Low Levels of High-Density Lipoprotein Cholesterol and Long-term Outcomes of Patients With Acute Coronary Syndrome Treated Without Revascularization: Insights From the TRILOGY ACS Trial. 
  • Association between hospital process performance and outcomes among patients with acute coronary syndromes. 
  • Association of diabetes mellitus and glycemic control strategies with clinical outcomes after acute coronary syndromes. 
  • Association of intravenous morphine use and outcomes in acute coronary syndromes: results from the CRUSADE Quality Improvement Initiative. 
  • Association of obesity with cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease: Insights from TECOS. 
  • Associations between β-blocker therapy and cardiovascular outcomes in patients with diabetes and established cardiovascular disease. 
  • Atherosclerotic risk genotypes and recurrent coronary events after myocardial infarction. 
  • Attenuation of rebound ischemia after discontinuation of heparin therapy by glycoprotein IIb/IIIa inhibition with eptifibatide in patients with acute coronary syndromes: observations from the platelet IIb/IIIa in unstable angina: receptor suppression using integrilin therapy (PURSUIT) trial. 
  • Baseline Low-Density Lipoprotein Cholesterol and Clinical Outcomes of Combining Ezetimibe With Statin Therapy in IMPROVE-IT. 
  • Baseline risk of major bleeding in non-ST-segment-elevation myocardial infarction: the CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA Guidelines) Bleeding Score. 
  • Beneficial effects of noetic therapies on mood before percutaneous intervention for unstable coronary syndromes. 
  • Bivalirudin for patients with acute coronary syndromes. 
  • Brazilian Society of Cardiology Guidelines on Unstable Angina and Acute Myocardial Infarction without ST-Segment Elevation - 2021. 
  • Building evidence for early initiation of clopidogrel loading in non-ST-segment elevation acute coronary syndromes: going past the American College of Cardiology/American Heart Association guidelines. 
  • C-reactive protein: a novel marker of cardiovascular risk. 
  • Canadian-American differences in the management of acute coronary syndromes in the GUSTO IIb trial: one-year follow-up of patients without ST-segment elevation. Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) II Investigators. 
  • Care of non-ST-segment elevation patients: insights from the CRUSADE national quality improvement initiative. 
  • Case 2--1997. On-line contrast echocardiographic assessment of myocardial perfusion: its role in minimally invasive coronary artery bypass procedures. 
  • Case 2-2002. Thoracic epidural anesthesia in patients with ankylosing spondylitis undergoing coronary artery surgery. 
  • Changes in glycoprotein IIb/IIIa inhibitor excess dosing with site-specific safety feedback in the Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA guidelines (CRUSADE) initiative. 
  • Changing the model of care for patients with acute coronary syndromes. 
  • Characterization and outcomes of women and men with non-ST-segment elevation myocardial infarction and nonobstructive coronary artery disease: results from the Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes with Early Implementation of the ACC/AHA Guidelines (CRUSADE) quality improvement initiative. 
  • Characterization of cardiovascular clinical events and impact of event adjudication on the treatment effect of darapladib versus placebo in patients with stable coronary heart disease: Insights from the STABILITY trial. 
  • Clinical association between renal insufficiency and positive troponin I in patients with acute coronary syndrome. 
  • Clinical characteristics, process of care, and outcomes of Hispanic patients presenting with non-ST-segment elevation acute coronary syndromes: results from Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA Guidelines (CRUSADE). 
  • Clinical significance of thrombocytopenia during a non-ST-elevation acute coronary syndrome. The platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrilin therapy (PURSUIT) trial experience. 
  • Clinical trial--derived risk model may not generalize to real-world patients with acute coronary syndrome. 
  • Clinical, electrocardiographic, and biochemical data for immediate risk stratification in acute coronary syndromes. 
  • Clopidogrel to treat patients with non-ST-segment elevation acute coronary syndromes after hospital discharge. 
  • Combined TMR and mitral valve replacement via left thoracotomy. 
  • Comparison of baseline characteristics, treatment patterns, and in-hospital outcomes of Asian versus non-Asian white Americans with non-ST-segment elevation acute coronary syndromes from the CRUSADE quality improvement initiative. 
  • Comparison of benefits and complications of hirudin versus heparin for patients with acute coronary syndromes undergoing early percutaneous coronary intervention. 
  • Comparison of fondaparinux and enoxaparin in acute coronary syndromes. 
  • Comparison of medicine alone, coronary angioplasty, and left internal mammary artery-coronary artery bypass for one-vessel proximal left anterior descending coronary artery disease. 
  • Comparison of outcomes of patients with acute coronary syndromes with and without atrial fibrillation. 
  • Comparison of sibrafiban with aspirin for prevention of cardiovascular events after acute coronary syndromes: a randomised trial. The SYMPHONY Investigators. Sibrafiban versus Aspirin to Yield Maximum Protection from Ischemic Heart Events Post-acute Coronary Syndromes. 
  • Comparison of visual assessment of coronary stenosis with independent quantitative coronary angiography: Findings from the Prospective Multicenter Imaging Study for Evaluation of Chest Pain (PROMISE) trial. 
  • Conflicting results between randomized trials and observational studies on the impact of proton pump inhibitors on cardiovascular events when coadministered with dual antiplatelet therapy: systematic review. 
  • Coordinated series of studies to evaluate characteristics and mechanisms of acute coronary syndromes in high-risk patients randomly assigned to enoxaparin or unfractionated heparin: design and rationale of the SYNERGY Library. 
  • Coronary artery angioplasty with a helical autoperfusion balloon catheter. 
  • Correlations between preprocedure mood and clinical outcome in patients undergoing coronary angioplasty. 
  • Cost and cost-effectiveness of an early invasive vs conservative strategy for the treatment of unstable angina and non-ST-segment elevation myocardial infarction. 
  • Cost effectiveness in Canada of eptifibatide treatment for acute coronary syndrome patients using PURSUIT subgroup analysis. 
  • Cost-effectiveness of platelet glycoprotein IIb/IIIa inhibition with eptifibatide in patients with non-ST-elevation acute coronary syndromes. 
  • Current knowledge of the platelet glycoprotein IIb/IIIa receptor antagonists for the treatment of coronary artery disease. 
  • Cyclic coronary flow: defining preinfarction angina at the crossroads of unstable angina and myocardial infarction. 
  • Decline in rates of death and heart failure in acute coronary syndromes, 1999-2006. 
  • Detection of silent ischemia adds to the prognostic value of coronary anatomy and left ventricular function in predicting outcome in unstable angina patients. 
  • Diagnosing and managing unstable angina. Agency for Health Care Policy and Research. 
  • Differences between men and women in the management of unstable angina pectoris (The GUARANTEE Registry). The GUARANTEE Investigators. 
  • Differences in admission rates and outcomes between men and women presenting to emergency departments with coronary syndromes. 
  • Differences in short-term versus long-term outcomes of older black versus white patients with myocardial infarction: findings from the Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes with Early Implementation of American College of Cardiology/American Heart Association Guidelines (CRUSADE). 
  • Differential expression of tissue factor protein in directional atherectomy specimens from patients with stable and unstable coronary syndromes. 
  • Disappearing and reappearing differences in drug-eluting stent use by race. 
  • Discordances between predicted and actual risk in obese patients with suspected cardiac ischaemia. 
  • Does chronic Chlamydia pneumoniae infection increase the risk of myocardial injury? Insights from patients with non-ST-elevation acute coronary syndromes. 
  • Does eptifibatide confer a greater benefit to patients with unstable angina than with non-ST segment elevation myocardial infarction? Insights from the PURSUIT Trial. 
  • Door-to-ECG time in patients with chest pain presenting to the ED. 
  • Dynamic prognostication in non-ST-elevation acute coronary syndromes: insights from GUSTO-IIb and PURSUIT. 
  • Early discontinuation of prasugrel or clopidogrel in acute coronary syndromes: insights from the TRILOGY ACS trial. 
  • Early statin initiation and outcomes in patients with acute coronary syndromes. 
  • Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trial. 
  • Effect of eptifibatide for acute coronary syndromes: rapid versus late administration--therapeutic yield on platelets (The EARLY Platelet Substudy). 
  • Effect of institutional volume and academic status on outcomes of coronary interventions: the IMPACT-II experience. 
  • Effect of intensive lipid-lowering therapy on mortality after acute coronary syndrome (a patient-level analysis of the Aggrastat to Zocor and Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 trials). 
  • Effect of lipid-lowering therapy on early mortality after acute coronary syndromes: an observational study. 
  • Effects of Proprotein Convertase Subtilisin/Kexin Type 9 Antibodies in Adults With Hypercholesterolemia: A Systematic Review and Meta-analysis. 
  • Effects of early treatment with statins on short-term clinical outcomes in acute coronary syndromes: a meta-analysis of randomized controlled trials. 
  • Effects of initial invasive vs. initial conservative treatment strategies on recurrent and total cardiovascular events in the ISCHEMIA trial. 
  • Efficacy and bleeding complications among patients randomized to enoxaparin or unfractionated heparin for antithrombin therapy in non-ST-Segment elevation acute coronary syndromes: a systematic overview. 
  • Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: results from the OASIS-5 trial. 
  • Efficacy and safety of minimal dose (< or =1,000 units) unfractionated heparin with abciximab in percutaneous coronary intervention. 
  • Elevated body mass index and intermediate-term clinical outcomes after acute coronary syndromes. 
  • Elevated creatine kinase-MB with normal creatine kinase predicts worse outcomes in patients with acute coronary syndromes: results from 4 large clinical trials. 
  • Emerging treatment of acute coronary syndromes with platelet glycoprotein IIB/IIIA inhibitors. 
  • Enhancing Cardiac Rehabilitation With Stress Management Training: A Randomized, Clinical Efficacy Trial. 
  • Evaluation of CRUSADE and ACUITY-HORIZONS Scores for Predicting Long-term Out-of-Hospital Bleeding after Percutaneous Coronary Interventions. 
  • Evolution in cardiovascular care for elderly patients with non-ST-segment elevation acute coronary syndromes: results from the CRUSADE National Quality Improvement Initiative. 
  • Excess dosing of antiplatelet and antithrombin agents in the treatment of non-ST-segment elevation acute coronary syndromes. 
  • Extent of, and factors associated with, delay to hospital presentation in patients with acute coronary disease (the GRACE registry). 
  • Factors related to heart rupture in acute coronary syndromes in the Global Registry of Acute Coronary Events. 
  • Failure of adjuvant heparin to reduce myocardial ischemia in the early treatment of patients with unstable angina. 
  • Frequency of transient reductions in left ventricular ejection fraction at rest in coronary artery disease. 
  • Frequency, predictors, and outcomes of drug-eluting stent utilization in patients with high-risk non-ST-segment elevation acute coronary syndromes. 
  • Gender differences in the treatment of non-ST-segment elevation myocardial infarction. 
  • Gender disparities in the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes: large-scale observations from the CRUSADE (Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes With Early Implementation of the American College of Cardiology/American Heart Association Guidelines) National Quality Improvement Initiative. 
  • Glycoprotein IIb/IIIa inhibitors in acute coronary syndromes. 
  • Glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: pathophysiologic foundation and clinical findings. 
  • Hand-held echocardiographic examination of patients with symptoms of acute coronary syndromes in the emergency department: the 30-day outcome associated with normal left ventricular wall motion. 
  • Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. 
  • Heparin in acute coronary disease--requiem for a heavyweight? 
  • Heparins: their established role in acute coronary syndromes and perspectives in atrial fibrillation. 
  • How should a patient presenting with unstable angina and a recent stroke be managed? 
  • ISIS-4. 
  • Impact of age on management and outcome of acute coronary syndrome: observations from the Global Registry of Acute Coronary Events (GRACE). 
  • Impact of candesartan on nonfatal myocardial infarction and cardiovascular death in patients with heart failure. 
  • Impact of combined pharmacologic treatment with clopidogrel and a statin on outcomes of patients with non-ST-segment elevation acute coronary syndromes: perspectives from a large multinational registry. 
  • Impact of congestive heart failure in patients with non-ST-segment elevation acute coronary syndromes. 
  • Impact of different patterns of invasive care on quality of life outcomes in patients with non-ST elevation acute coronary syndrome: results from the GUSTO-IIb Canada-United States substudy. 
  • Impact of hospitalization for acute coronary events on subsequent mortality in patients with chronic heart failure. 
  • Impact of sex on long-term mortality from acute myocardial infarction vs unstable angina. 
  • Improving acute coronary syndrome care: the ACC/AHA guidelines and critical pathways. 
  • Improving efficiency of inferences in randomized clinical trials using auxiliary covariates. 
  • Improving the care of patients with non-ST-elevation acute coronary syndromes in the emergency department: the CRUSADE initiative. 
  • In-hospital revascularization and one-year outcome of acute coronary syndrome patients stratified by the GRACE risk score. 
  • Incidence and characteristics of stroke during 90-day follow-up in patients stabilized after an acute coronary syndrome. 
  • Incidence and prognostic significance of thrombocytopenia developed during acute coronary syndrome in contemporary clinical practice. 
  • Influence of insurance type on the use of procedures, medications and hospital outcome in patients with unstable angina: results from the GUARANTEE Registry. Global Unstable Angina Registry and Treatment Evaluation. 
  • Influence of timing of troponin elevation on clinical outcomes and use of evidence-based therapies for patients with non-ST-segment elevation acute coronary syndromes. 
  • Influence of transfer-in rates on quality of care and outcomes at receiving hospitals in patients with non-ST-segment elevation myocardial infarction. 
  • Initial Invasive or Conservative Strategy for Stable Coronary Disease. 
  • Initiation of hormone replacement therapy after acute myocardial infarction is associated with more cardiac events during follow-up. 
  • Intracoronary bolus administration of eptifibatide during percutaneous coronary stenting for non ST elevation myocardial infarction and unstable angina. 
  • Intracoronary thrombus and complex morphology in unstable angina. Relation to timing of angiography and in-hospital cardiac events. 
  • Left ventricular long axis function assessed during cine-cardiovascular magnetic resonance is an independent predictor of adverse cardiac events. 
  • Lesion-directed administration of alteplase with intracoronary heparin in patients with unstable angina and coronary thrombus undergoing angioplasty. 
  • Lessons from SADHART, ENRICHD, and other trials. 
  • Lipid management in patients with unstable angina pectoris and non-ST-segment elevation acute myocardial infarction (from CRUSADE). 
  • Long-Term Bleeding Risk Prediction with Dual Antiplatelet Therapy After Acute Coronary Syndromes Treated Without Revascularization. 
  • Long-term oral platelet glycoprotein IIb/IIIa receptor antagonism with sibrafiban after acute coronary syndromes: study design of the sibrafiban versus aspirin to yield maximum protection from ischemic heart events post-acute coronary syndromes (SYMPHONY) trial. Symphony Steering Committee. 
  • Long-term outcomes for women versus men with unstable angina/non-ST-segment elevation myocardial infarction managed medically without revascularization: insights from the TaRgeted platelet Inhibition to cLarify the Optimal strateGy to medicallY manage Acute Coronary Syndromes trial. 
  • Long-term results after the glycoprotein IIb/IIIa inhibitor abciximab in unstable angina: one-year survival in the GUSTO IV-ACS (Global Use of Strategies To Open Occluded Coronary Arteries IV--Acute Coronary Syndrome) Trial. 
  • Low-molecular-weight heparin versus unfractionated heparin for unstable coronary disease. 
  • Magnesium therapy for refractory ventricular fibrillation. 
  • Medication performance measures and mortality following acute coronary syndromes. 
  • Meta-analysis of multitreatment studies. 
  • Missed diagnoses of acute coronary syndromes in the emergency room--continuing challenges. 
  • National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: Clinical characteristics and utilization of biochemical markers in acute coronary syndromes. 
  • National Academy of Clinical Biochemistry and IFCC Committee for Standardization of Markers of Cardiac Damage Laboratory Medicine Practice Guidelines: Analytical issues for biochemical markers of acute coronary syndromes. 
  • Neovascularization in atherectomy specimens from patients with unstable angina: implications for pathogenesis of unstable angina. 
  • New heparin dosing recommendations for patients with acute coronary syndromes. 
  • No prognostic significance of chronic infection with Chlamydia pneumoniae in acute coronary syndromes: insights from the Global Utilization of Strategies to Open Occluded Arteries IV Acute Coronary Syndromes trial. 
  • Non-ST-elevation myocardial infarction patients who present during off hours have higher risk profiles and are treated less aggressively, but their outcomes are not worse: a report from Can Rapid Risk Stratification of Unstable Angina Patients Suppress ADverse Outcomes with Early Implementation of the ACC/AHA Guidelines CRUSADE initiative. 
  • Optimal timing of intervention in non-ST-segment elevation acute coronary syndromes: insights from the CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA guidelines) Registry. 
  • Optimising outcomes: socioeconomic perspective. 
  • Oral platelet glycoprotein IIb/IIIa inhibition. 
  • Outcomes of anatomical versus functional testing for coronary artery disease. 
  • Outcomes of patients with acute coronary syndromes and prior coronary artery bypass grafting: results from the platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrilin therapy (PURSUIT) trial. 
  • Overcoming the challenges facing quality-improvement strategies for non-ST-segment elevation acute coronary syndromes. 
  • Paradoxical use of invasive cardiac procedures for patients with non-ST segment elevation myocardial infarction: an international perspective from the CRUSADE Initiative and the Canadian ACS Registries I and II. 
  • Patient risk or physician practice: what factors drive resource use in unstable angina? 
  • Patterns and prognostic implications of low high-density lipoprotein levels in patients with non-ST-segment elevation acute coronary syndromes. 
  • Patterns of aspirin dosing in non-ST-elevation acute coronary syndromes in the CRUSADE Quality Improvement Initiative. 
  • Patterns of guideline adherence and care delivery for patients with unstable angina and non-ST-segment elevation myocardial infarction (from the CRUSADE Quality Improvement Initiative). 
  • Percutaneous coronary intervention versus coronary bypass graft surgery for diabetic patients with unstable angina and risk factors for adverse outcomes with bypass: outcome of diabetic patients in the AWESOME randomized trial and registry. 
  • Percutaneous revascularization of an extensively diseased saphenous vein bypass graft with a saphenous vein-covered Palmaz stent. 
  • Percutaneous transluminal coronary angioplasty in women compared with men. 
  • Persistence of the prothrombotic state after acute coronary syndromes: implications for treatment. 
  • Pharmacoeconomic analysis of sertraline treatment of depression in patients with unstable angina or a recent myocardial infarction. 
  • Pharmacoinvasive management of acute coronary syndrome in the setting of percutaneous coronary intervention: evidence-based, site- and spectrum-of-care strategies for optimizing patient outcomes in NSTE-ACS. 
  • Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials. 
  • Platelet glycoprotein IIb/IIIa integrin blockade: recent clinical trials in interventional cardiology. 
  • Practical implementation of the Guidelines for Unstable Angina/Non-ST-Segment Elevation Myocardial Infarction in the emergency department. 
  • Prasugrel versus clopidogrel for acute coronary syndromes without revascularization. 
  • Prasugrel versus clopidogrel for acute coronary syndromes. 
  • Prasugrel versus clopidogrel for patients with unstable angina or non-ST-segment elevation myocardial infarction with or without angiography: a secondary, prespecified analysis of the TRILOGY ACS trial. 
  • Pre-hospital synthesized 12-lead ECG ischemia monitoring with trans-telephonic transmission in acute coronary syndromes: pilot study results of the ST SMART trial. 
  • Predicting a late positive serum troponin in initially troponin-negative patients with non-ST-elevation acute coronary syndrome: clinical predictors and validated risk score results from the TIMI IIIB and GUSTO IIA studies. 
  • Predictors of recurrent ischemic events and death in unstable coronary artery disease after treatment with combination antithrombotic therapy. 
  • Present and evolving role of eptifibatide in the treatment of acute coronary syndromes. 
  • Presenting Symptoms in Patients Undergoing Coronary Artery Disease Evaluation: Association With Noninvasive Test Results and Clinical Outcomes in the PROMISE Trial. 
  • Prevalence and management of hypertension in acute coronary syndrome patients varies by sex: observations from the Sibrafiban versus aspirin to Yield Maximum Protection from ischemic Heart events postacute cOroNary sYndromes (SYMPHONY) randomized clinical trials. 
  • Prevalence, predictors, and outcomes of patients with non-ST-segment elevation myocardial infarction and insignificant coronary artery disease: results from the Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA Guidelines (CRUSADE) initiative. 
  • Prior aspirin use predicts worse outcomes in patients with non-ST-elevation acute coronary syndromes. PURSUIT Investigators. Platelet IIb/IIIa in Unstable angina: Receptor Suppression Using Integrilin Therapy. 
  • Prognosis in medically stabilized unstable angina: early Holter ST-segment monitoring compared with predischarge exercise thallium tomography. 
  • Prognostic Value of Coronary Artery Calcium in the PROMISE Study (Prospective Multicenter Imaging Study for Evaluation of Chest Pain). 
  • Prognostic importance of concomitant heparin with eptifibatide in acute coronary syndromes. PURSUIT Investigators. Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy. 
  • Prognostic significance of elevated troponin I after percutaneous coronary intervention. 
  • Prognostic value of ST segment depression in acute coronary syndromes: insights from PARAGON-A applied to GUSTO-IIb. PARAGON-A and GUSTO IIb Investigators. Platelet IIb/IIIa Antagonism for the Reduction of Acute Global Organization Network. 
  • Prospective comparison of hemorrhagic complications after treatment with enoxaparin versus unfractionated heparin for unstable angina pectoris or non-ST-segment elevation acute myocardial infarction. 
  • Pursuing progress in acute coronary syndromes. 
  • Racial differences in long-term outcomes among black and white patients with drug-eluting stents. 
  • Racial differences in the management of unstable angina: results from the multicenter GUARANTEE registry. 
  • Randomisation in the SYMPHONY trial. 
  • Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE Study. 
  • Randomized COMparison of platelet inhibition with abciximab, tiRofiban and eptifibatide during percutaneous coronary intervention in acute coronary syndromes: the COMPARE trial. Comparison Of Measurements of Platelet aggregation with Aggrastat, Reopro, and Eptifibatide. 
  • Randomized evaluation of the efficacy of enoxaparin versus unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes receiving the glycoprotein IIb/IIIa inhibitor eptifibatide. Long-term results of the Integrilin and Enoxaparin Randomized Assessment of Acute Coronary Syndrome Treatment (INTERACT) trial. 
  • Rationale and clinical evidence for the use of GP IIb/IIIa inhibitors in acute coronary syndromes. 
  • Rationale, design, and organization of a randomized, controlled Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) in patients with type 2 diabetes and established cardiovascular disease. 
  • Rebound increase in thrombin generation and activity after cessation of intravenous heparin in patients with acute coronary syndromes. 
  • Recent trends in the care of patients with non-ST-segment elevation acute coronary syndromes: insights from the CRUSADE initiative. 
  • Recent update to the ACC/AHA guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction: role of antiplatelet therapy. 
  • Recurrent ischemia during continuous 12-lead ECG-ischemia monitoring in patients with acute coronary syndromes treated with eptifibatide: relation with death and myocardial infarction. PURSUIT ECG-Ischemia Monitoring Substudy Investigators. Platelet glycoprotein IIb/IIIa in Unstable angina: Receptor Suppression Using Integrilin Therapy. 
  • Relation of angiographic detected intracoronary thrombus and silent myocardial ischemia in unstable angina pectoris. 
  • Relation of timing of cardiac catheterization to outcomes in patients with non-ST-segment elevation myocardial infarction or unstable angina pectoris enrolled in the multinational global registry of acute coronary events. 
  • Relationship between age and platelet activation in patients with stable and unstable angina. 
  • Relationship between risk stratification by cardiac troponin level and adherence to guidelines for non-ST-segment elevation acute coronary syndromes. 
  • Relationship of Platelet Reactivity With Bleeding Outcomes During Long-Term Treatment With Dual Antiplatelet Therapy for Medically Managed Patients With Non-ST-Segment Elevation Acute Coronary Syndromes. 
  • Representation of elderly persons and women in published randomized trials of acute coronary syndromes. 
  • Risk stratification in acute coronary syndromes: the need for continued vigilance in "low-risk" patients. 
  • Role of coronary angiography in acute coronary artery syndromes. 
  • Role of resting thallium201 perfusion in predicting coronary anatomy, left ventricular wall motion, and hospital outcome in unstable angina pectoris. 
  • Roundtable panel discussion: the role of glycoprotein IIb-IIIa receptor inhibitors in acute ischemic coronary syndromes. 
  • Routine upstream initiation vs deferred selective use of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: the ACUITY Timing trial. 
  • ST segment shift in unstable angina: pathophysiology and association with coronary anatomy and hospital outcome. 
  • ST-segment monitoring in patients with acute coronary syndromes. 
  • Sertraline for treatment of depression in acute coronary syndromes. 
  • Sertraline treatment of major depression in patients with acute MI or unstable angina. 
  • Sex Differences in Functional and CT Angiography Testing in Patients With Suspected Coronary Artery Disease. 
  • Sex differences in major bleeding with glycoprotein IIb/IIIa inhibitors: results from the CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA guidelines) initiative. 
  • Sex differences in patients seeking medical attention for prodromal symptoms before an acute coronary event. 
  • Should selective serotonin reuptake inhibitors be prescribed to all patients with ischemic heart disease? 
  • Statin Treatment by Low-Density Lipoprotein Cholesterol Levels in Patients With Non-ST-Segment Elevation Myocardial Infarction/Unstable Angina Pectoris (from the CRUSADE Registry). 
  • Strategies of patient care in acute coronary syndromes: rationale for the Global Registry of Acute Coronary Events (GRACE) registry. 
  • Stroke in patients with acute coronary syndromes: incidence and outcomes in the platelet glycoprotein IIb/IIIa in unstable angina. Receptor suppression using integrilin therapy (PURSUIT) trial. The PURSUIT Investigators. 
  • Study design and rationale of a comparison of prasugrel and clopidogrel in medically managed patients with unstable angina/non-ST-segment elevation myocardial infarction: the TaRgeted platelet Inhibition to cLarify the Optimal strateGy to medicallY manage Acute Coronary Syndromes (TRILOGY ACS) trial. 
  • Success stories: how hospitals are improving care. 
  • Taking the ACC/AHA guidelines for care of Acute Myocardial Infarction to the bedside: the GAP projects in southeastern Michigan. 
  • Temporal changes in the use of drug-eluting stents for patients with non-ST-Segment-elevation myocardial infarction undergoing percutaneous coronary intervention from 2006 to 2008: results from the can rapid risk stratification of unstable angina patients supress ADverse outcomes with early implementation of the ACC/AHA guidelines (CRUSADE) and acute coronary treatment and intervention outcomes network-get with the guidelines (ACTION-GWTG) registries. 
  • Temporal trends in and factors associated with bleeding complications among patients undergoing percutaneous coronary intervention: a report from the National Cardiovascular Data CathPCI Registry. 
  • The Editor's Roundtable: arterial thrombosis and acute coronary syndromes. 
  • The anticoagulant therapy with bivalirudin to assist in the performance of percutaneous coronary intervention in patients with heparin-induced thrombocytopenia (ATBAT) study: main results. 
  • The chest-pain unit--ready for prime time? 
  • The current practice of intra-aortic balloon counterpulsation: results from the Benchmark Registry. 
  • The early glycoprotein IIb/IIIa inhibition in non-ST-segment elevation acute coronary syndrome (EARLY ACS) trial: a randomized placebo-controlled trial evaluating the clinical benefits of early front-loaded eptifibatide in the treatment of patients with non-ST-segment elevation acute coronary syndrome--study design and rationale. 
  • The evolution of medical and surgical therapy for coronary artery disease. A 15-year perspective. 
  • The health care burden of unstable angina. 
  • The impact of clinical vs administrative claims coding on hospital risk-adjusted outcomes. 
  • The impact of for-profit hospital status on the care and outcomes of patients with non-ST-segment elevation myocardial infarction: results from the CRUSADE Initiative. 
  • The implications of blood transfusions for patients with non-ST-segment elevation acute coronary syndromes: results from the CRUSADE National Quality Improvement Initiative. 
  • The influence of risk status on guideline adherence for patients with non-ST-segment elevation acute coronary syndromes. 
  • The lack of science behind the standard of care. 
  • The obesity paradox in non-ST-segment elevation acute coronary syndromes: results from the Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the American College of Cardiology/American Heart Association Guidelines Quality Improvement Initiative. 
  • The prognostic value of creatine kinase elevations extends across the whole spectrum of acute coronary syndromes. 
  • The prognostic value of the admission and predischarge electrocardiogram in acute coronary syndromes: the GUSTO-IIb ECG Core Laboratory experience. 
  • The truth and consequences of the COURAGE trial. 
  • Thrombolysis in unstable angina. Randomized double-blind trial of t-PA and placebo. 
  • Thrombolytic therapy and unstable angina. 
  • Thrombolytic, antithrombin, and antiplatelet treatment of acute coronary syndromes. 
  • Timing of and risk factors for myocardial ischemic events after percutaneous coronary intervention (IMPACT-II). Integrilin to Minimize Platelet Aggregation and Coronary Thrombosis. 
  • Timing of death and myocardial infarction in patients with non-ST elevation acute coronary syndromes: insights from randomized clinical trials. 
  • Timing of glycoprotein IIb/IIIa inhibitor use and outcomes among patients with non-ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention (results from CRUSADE). 
  • Transient platelet aggregation as a mechanism of unstable angina. Aggressive treatment with coronary angioplasty. 
  • Translation of acute coronary syndrome therapies: from evidence to routine clinical practice. 
  • Treating patients with acute coronary syndromes with aggressive antiplatelet therapy (from the Global Registry of Acute Coronary Events). 
  • Two instruments to determine activated partial thromboplastin time: implications for heparin monitoring. 
  • Ultrastructural studies of unstable angina in living man. 
  • Understanding racial variation in the use of coronary revascularization procedures: the role of clinical factors. 
  • Unstable angina--report from a Canadian expert roundtable. 
  • Use of and inhospital outcomes after early clopidogrel therapy in patients not undergoing an early invasive strategy for treatment of non-ST-segment elevation myocardial infarction: results from Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the American College of Cardiology/American Heart Association guidelines (CRUSADE). 
  • Use of evidence-based medicine for acute coronary syndromes in the elderly and very elderly: insights from the Sibrafiban vs aspirin to Yield Maximum Protection from ischemic Heart events postacute cOroNary sYndromes trials. 
  • Use of proven therapies in non-ST-elevation acute coronary syndromes according to evidence-based risk stratification. 
  • Usefulness of combining necrosis and platelet markers in triaging patients presenting with chest pain to the emergency department. 
  • Usefulness of exercise electrocardiography and thallium scintigraphy in unstable angina pectoris in predicting the extent and severity of coronary artery disease. 
  • Using biomarkers to assess risk and consider treatment strategies in non-ST-segment elevation acute coronary syndromes. 
  • Utilization of early invasive management strategies for high-risk patients with non-ST-segment elevation acute coronary syndromes: results from the CRUSADE Quality Improvement Initiative. 
  • Validity of reported genetic risk factors for acute coronary syndrome. 
  • Value of radionuclide angiography for predicting specific cardiac events after acute myocardial infarction. 
  • We need to do better for patients with non-ST-segment elevation acute coronary syndrome who are managed without revascularization. 
  • Weight-based dosing of enoxaparin in obese patients with non-ST-segment elevation acute coronary syndromes: results from the CRUSADE initiative. 
• 

  Keywords of People

  • Alexander, John Hunter Peel, Professor of Medicine, Medicine, Cardiology
  • Granger, Christopher Bull, Professor of Medicine, School of Nursing
  • Laskowitz, Daniel Todd, Professor of Neurology, Duke Science & Society
  • O'Connor, Christopher Michael, Adjunct Professor in the Department of Medicine, Medicine, Clinical Pharmacology
  • Stinnett, Sandra Sue, Associate Professor of Biostatistics & Bioinformatics, Biostatistics & Bioinformatics
  • Yancy Jr., William Samuel, Professor of Medicine, Medicine, General Internal Medicine